LakeShore Biopharma Lowers Merger Price to $0.066 Per Share in Revised Going-Private Deal

LakeShore Biopharma Co., Ltd, a global biopharmaceutical company focused on vaccines and therapeutic biologics, has entered into an amended merger agreement that slashes the per-share consideration from $0.90 to $0.066, according to a press release issued today. The revised deal, which implies an equity value of approximately $2.7 million, follows a revised proposal from the buyer group received on March 24, 2026.

Under the amended agreement, Oceanpine Merger Sub Inc. will merge with and into LakeShore Biopharma, with the company surviving as a wholly owned subsidiary of Oceanpine Skyline Inc. The buyer group includes Oceanpine Investment Fund II LP, Oceanpine Capital Inc., Crystal Peak Investment Inc., and several other investment funds. The merger consideration per share represents a 46.7% premium over the closing price on March 24, 2026, the day before the revised proposal was announced, and a 23.3% premium over the volume-weighted average price for the prior 10 trading days.

The amendment also extends the termination date to nine months from the date of the amended agreement and reduces the termination fees: the company will pay $50,000 if it terminates, and the parent will pay $100,000. The merger is expected to close in the third quarter of 2026, subject to approval by at least two-thirds of votes cast by shareholders at a general meeting. Rollover shareholders, holding approximately 53.35% of voting rights, have agreed to vote in favor.

The board of directors, acting on the unanimous recommendation of a special committee of independent directors, approved the amended merger agreement. The special committee, advised by Kroll, LLC as financial advisor and Gibson, Dunn & Crutcher LLP as U.S. legal counsel, negotiated the terms. “The special committee evaluated the revised proposal and negotiated the terms of the amended merger agreement with the assistance of its financial and legal advisors,” the company stated.

If completed, the merger will take LakeShore Biopharma private, and its shares will no longer be quoted on the OTC Pink Open Market. The company trades under tickers OTCPK: LSBCF and OTCPK: LSBWF. The transaction will be funded through a cash contribution from Oceanpine Capital Inc. and an equity rollover by the rollover shareholders.

LakeShore Biopharma, previously known as YS Biopharma, operates in China, Singapore, and the Philippines, focusing on its proprietary PIKA immunomodulating technology platform for vaccines against rabies, hepatitis B, influenza, and other viruses. The company will file a current report on Form 6-K with the U.S. Securities and Exchange Commission (SEC) containing the amended merger agreement. A proxy statement and a Schedule 13E-3 transaction statement will be mailed to shareholders and filed with the SEC. Investors are urged to read these documents carefully when available at the SEC’s website (http://www.sec.gov).

The amended deal highlights the challenges faced by smaller biopharmaceutical firms in public markets, as LakeShore Biopharma moves to privatize at a significantly reduced valuation. The company’s forward-looking statements caution that actual results may differ due to risks including competing offers, financing availability, and satisfaction of closing conditions, as detailed in its SEC filings.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is LakeShore Biopharma Lowers Merger Price to $0.066 Per Share in Revised Going-Private Deal.

The post LakeShore Biopharma Lowers Merger Price to $0.066 Per Share in Revised Going-Private Deal appeared first on citybuzz.